Response to “Three drugs are unnecessary for treating paucibacillary leprosy—A critique of the WHO guidelines”
Open Access
- 4 June 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Neglected Tropical Diseases
- Vol. 14 (6), e0008169
- https://doi.org/10.1371/journal.pntd.0008169
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A 19-Year retrospective study of adverse drug reactions to multidrug therapy in leprosy requiring a change in regimeIndian Dermatology Online Journal, 2018
- Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patientsPLoS Neglected Tropical Diseases, 2017
- WHO Multidrug Therapy for Leprosy: Epidemiology of Default in Treatment in Agra District, Uttar Pradesh, IndiaBioMed Research International, 2015
- Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effectsMemórias do Instituto Oswaldo Cruz, 2012
- Six months fixed duration multidrug therapy in paucibacillary leprosy: risk of relapse and disability in Agra PB cohort studyBMJ Open, 2012
- Relapse in leprosyIndian Journal of Dermatology, Venereology and Leprology, 2009
- A study on trend of relapse in leprosy and factors influencing relapse.2005
- MDT-MB therapy in paucibacillary leprosy: A clinicopathological assessmentIndian Journal of Dermatology, Venereology and Leprology, 2005
- Chemotherapy trial in paucibacillary leprosy using clofazimine.2000
- Relapses in paucibacillary leprosy after MDT--a clinical study.1990